Cargando…

Effect of Vitamin D Supplementation on Skeletal Muscle Volume and Strength in Patients with Decompensated Liver Cirrhosis Undergoing Branched Chain Amino Acids Supplementation: A Prospective, Randomized, Controlled Pilot Trial

Background: Sarcopenia worsens patient prognoses in chronic liver disease. This study aimed to elucidate the effects of vitamin D supplementation on skeletal muscle volume and strength in patients with decompensated cirrhosis. Methods: Thirty-three patients were entered into the study based on the c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okubo, Tomomi, Atsukawa, Masanori, Tsubota, Akihito, Ono, Hiroki, Kawano, Tadamichi, Yoshida, Yuji, Arai, Taeang, Hayama, Korenobu, Itokawa, Norio, Kondo, Chisa, Kaneko, Keiko, Iwakiri, Katsuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8228227/ https://www.ncbi.nlm.nih.gov/pubmed/34070910 http://dx.doi.org/10.3390/nu13061874

Ejemplares similares

How do the 2022 European Society of Cardiology/European Respiratory Society guidelines modify the diagnosis of portopulmonary hypertension in patients with cirrhosis complicated by portal hypertension? A post hoc analysis
por: Atsukawa, Masanori, et al.
Publicado: (2023)

Efficacy and safety of oral semaglutide in patients with non‐alcoholic fatty liver disease complicated by type 2 diabetes mellitus: A pilot study
por: Arai, Taeang, et al.
Publicado: (2022)

A novel formula used for predicting hepatocellular carcinoma after the achievement of sustained virologic response by direct-acting antivirals in patients with chronic hepatitis C
por: Yoshida, Yuji, et al.
Publicado: (2023)

Effect of sodium-glucose cotransporter 2 inhibitor in patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus: a propensity score-matched analysis of real-world data
por: Arai, Taeang, et al.
Publicado: (2021)

Factors influencing subclinical atherosclerosis in patients with biopsy-proven nonalcoholic fatty liver disease
por: Arai, Taeang, et al.
Publicado: (2019)

Liver fibrosis is associated with carotid atherosclerosis in patients with liver biopsy-proven nonalcoholic fatty liver disease
por: Arai, Taeang, et al.
Publicado: (2021)

Antifibrotic effect and long‐term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus
por: Arai, Taeang, et al.
Publicado: (2022)

Shorter pruritus period and milder disease stage are associated with response to nalfurafine hydrochloride in patients with chronic liver disease
por: Kawano, Tadamichi, et al.
Publicado: (2022)

Factors Associated with Hepatitis B Surface Antigen Kinetics and Responses in Pegylated Interferon Alpha-2a Monotherapy for Patients with Chronic Hepatitis B
por: Itokawa, Norio, et al.
Publicado: (2021)

A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C
por: Atsukawa, Masanori, et al.
Publicado: (2021)

Influencing factors on serum 25-hydroxyvitamin D(3) levels in Japanese chronic hepatitis C patients
por: Atsukawa, Masanori, et al.
Publicado: (2015)

Sequential therapy from entecavir to tenofovir alafenamide versus continuous entecavir monotherapy for patients with chronic hepatitis B
por: Itokawa, Norio, et al.
Publicado: (2020)

Anti-CD137 monoclonal antibody enhances trastuzumab-induced, natural killer cell-mediated cytotoxicity against pancreatic cancer cell lines with low human epidermal growth factor-like receptor 2 expression
por: Masu, Takushi, et al.
Publicado: (2018)

Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study
por: Atsukawa, Masanori, et al.
Publicado: (2013)

Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study
por: Atsukawa, Masanori, et al.
Publicado: (2020)

Usefulness of autotaxin for the complications of liver cirrhosis
por: Shao, Xue, et al.
Publicado: (2020)

Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C
por: Kato, Keizo, et al.
Publicado: (2019)

The Risk of Cirrhosis and Its Complications Based on PNPLA3 rs738409 G Allele Frequency
por: Shao, Xue, et al.
Publicado: (2022)

Insulin-like growth factor 1 predicts decompensation and long-term prognosis in patients with compensated cirrhosis
por: Saeki, Chisato, et al.
Publicado: (2023)

Trends and Efficacy of Interferon-Free Anti–hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan
por: Toyoda, Hidenori, et al.
Publicado: (2019)

Mac‐2‐binding protein glycan isomer predicts all malignancies after sustained virological response in chronic hepatitis C
por: Kawata, Kazuhito, et al.
Publicado: (2022)

Improving Survival in Decompensated Cirrhosis
por: Mukerji, Amar Nath, et al.
Publicado: (2012)

Management options in decompensated cirrhosis
por: Shah, Neeral L, et al.
Publicado: (2015)

COVID-19 in decompensated cirrhosis
por: Rela, Mohamed, et al.
Publicado: (2020)

Decompensation of Cirrhosis: An Unusual Cause
por: Rudra, Omkar S, et al.
Publicado: (2022)

Determination of ADAMTS13 and Its Clinical Significance for ADAMTS13 Supplementation Therapy to Improve the Survival of Patients with Decompensated Liver Cirrhosis
por: Uemura, Masahito, et al.
Publicado: (2011)

Type III procollagen peptide level can indicate liver dysfunction associated with volume overload in acute heart failure
por: Shirakabe, Akihiro, et al.
Publicado: (2022)

Improving Survival in Patients with Decompensated Cirrhosis
por: Amarapurkar, Deepak, et al.
Publicado: (2011)

Viusid, a nutritional supplement, increases survival and reduces disease progression in HCV-related decompensated cirrhosis: a randomised and controlled trial
por: Vilar Gomez, Eduardo, et al.
Publicado: (2011)

Gadoxetic acid-enhanced magnetic resonance imaging predicts hyperbilirubinemia induced by glecaprevir during hepatitis C virus treatment
por: Okubo, Hironao, et al.
Publicado: (2022)

Treatment of Hepatitis B in Decompensated Liver Cirrhosis
por: Guan, Richard, et al.
Publicado: (2011)

Prescribing Medications in Patients with Decompensated Liver Cirrhosis
por: Amarapurkar, Deepak N.
Publicado: (2011)

Management of Coagulopathy in Patients with Decompensated Liver Cirrhosis
por: Amarapurkar, Pooja D., et al.
Publicado: (2011)

Glycated Hemoglobin Levels in Patients with Decompensated Cirrhosis
por: Nadelson, Jeffrey, et al.
Publicado: (2016)

Frequency of gallstones and mean BMI in decompensated cirrhosis
por: Rai, Ayesha Aslam, et al.
Publicado: (2018)

Clinical impact of microbiome in patients with decompensated cirrhosis
por: Oikonomou, Theodora, et al.
Publicado: (2018)

Albumin in decompensated cirrhosis: new concepts and perspectives
por: Bernardi, Mauro, et al.
Publicado: (2020)

Micronutrient Deficiencies in Patients with Decompensated Liver Cirrhosis
por: Llibre-Nieto, Gemma, et al.
Publicado: (2021)

Acute Myeloid Leukemia Masquerading as Decompensated Cirrhosis
por: Ahdi, Hardeep S, et al.
Publicado: (2022)

Biomarkers of hepatocellular synthesis in patients with decompensated cirrhosis
por: Gurbuz, Berivan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jlfh6gscjcvevorjtvupfbkn8q